Kidney & Blood Pressure Research (Dec 2014)

Effects of Paricalcitol and Aliskiren Combination Therapy on Experimental Diabetic Nephropathy Model in Rats

  • Zehra Eren,
  • Mehmet Yalçin Günal,
  • Elif Arı Bakir,
  • Jale Coban,
  • Berrak Çağlayan,
  • Nur Ekimci,
  • Sinem Ethemoglu,
  • Ozgur Albayrak,
  • Tuba Akdeniz,
  • Gülderen Yanikkaya Demirel,
  • Ertuğrul Kiliç,
  • Gülçin Kantarci

DOI
https://doi.org/10.1159/000368471
Journal volume & issue
Vol. 39, no. 6
pp. 581 – 590

Abstract

Read online

Background/Aims: The aim of the present study was to investigate the effect of combination of aliskiren with paricalcitol on experimental diabetic nephropathy (DN) model in rats. Methods: Forty male Sprague Dawley rats were divided into 5 groups of 8 rats each, namely the control (Group C), diabetes (Group D), aliskiren (Group A), paricalcitol (Group P), and aliskiren plus paricalcitol (Group A+P) groups. Aliskiren was given by oral-gavage at a dose of 50 mg/kg/day once daily for 12 weeks. Paricalcitol was given by intraperitoneally at a dose of 0,4 µg/kg/three day of week for 12 weeks. Renal function parameters, oxidative stress biomarkers, mRNA expression of renin-angiotensin system parameters and kidney histology were determined. Results: Group A+P had lower mean albümin-to-creatinine ratio (ACR) (p=0.004) as well as higher creatinine clearance (CCr) (pConclusion: Our data seem to suggest a potential role of aliskiren plus paricalcitol acting synergystically for reducing the progression of diabetic nephropathy in an experimental rat model.

Keywords